Bristol-Myers Squibb Company
Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
Last updated:
Abstract:
The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
Status:
Grant
Type:
Utility
Filling date:
11 Sep 2014
Issue date:
21 Jan 2020